

- a) changing the amino acids;
- b) removal of said sequences;
- b) substitution of said sequences by the sequence Val-Glu-Pro-Ile-Pro (SEQ ID NO:6); or
- c) a combination of steps a), b) or c).

30. A dietary or pharmaceutical product according to claim 28 wherein the caseins do not contain the sequences Ser-Leu-Val-Tyr-Pro-Phe-Pro-Gly-Pro-Ile-His-Asn (SEQ ID NO:3) and Ser-Leu-Val-Tyr-Pro-Phe-Pro-Gly-Pro-Ile-Pro-Asn (SEQ ID NO:4).

31. A dietary or pharmaceutical product according to claim 28 further comprising at least one non-bovine casein or fragments thereof selected from the group consisting of naturally occurring, recombinant, synthetic animal or vegetable caseins not containing the sequences: Pro-Gly-Pro-Ile-His (SEQ ID NO:1) and Pro-Gly-Pro-Ile-Pro (SEQ ID NO:2).

32. A product according to claim 31 wherein the recombinant casein is obtained by the following steps: providing a vector suitable for the expression of the casein; transfecting said vector in a cell selected from the group consisting of prokaryotic cell, unicellular eukaryotic cell or a cell derived from a multi cellular organism; and isolating and purifying said casein.

*SUB E2*

33. A method for the prevention of insulin-dependent diabetes comprising the step of administering to newborn and infants an immunogenic infant formula free of caseins which exhibits molecular mimicry with protein GLUT2.

34. The method according to claim 33 wherein the infant formula is a milk which does not contain caseins containing the sequences: Pro-Gly-Pro-Ile-His (SEQ ID NO:1) and Pro-Gly-Pro-Ile-Pro (SEQ ID NO:2).

*SUB E3*

35. A method for the prevention of insulin-dependent diabetes